Tirzepatide, a Dual GIP and GLP-1 Receptor Agonist, Improves Markers of Beta-Cell Function and Insulin Sensitivity in Type 2 Diabetes Patients

被引：5
|
作者：
Thomas, Melissa K.
Nikooienejad, Amir
Bray, Ross
Cui, Xuewei
Wilson, Jonathan M.
Duffin, Kevin L.
Milicevic, Zvonko
Haupt, Axel
Robins, Deborah A.
机构：
来源：
DIABETES | 2019年 / 68卷
关键词：
D O I：
10.2337/db19-980-P
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
980-P
引用
收藏
页数：2
相关论文
共 50 条
  • [31] GIP and GLP-1 receptor agonism in the therapy of type 2 diabetes with a focus on tirzepatide
    Nauck, Michael A.
    Blueher, Matthias
    Meyhoefer, Sebastian M.
    Heitmann, Elke
    Goergens, Sven W.
    DIABETOLOGIE UND STOFFWECHSEL, 2023, 18 (06) : 475 - 487
  • [32] Tirzepatide, a dual GIP/GLP-1 receptor agonist, is effective and safe when added to basal insulin for treatment of type 2 diabetes (SURPASS-5)
    Dahl, D.
    Onishi, Y.
    Norwood, P.
    Huh, R.
    Patel, H.
    Rodriguez, A.
    DIABETOLOGIA, 2021, 64 (SUPPL 1) : 13 - 14
  • [33] Tirzepatide, a Dual GIP/GLP-1 Receptor Agonist, Is Effective and Safe When Added to Basal Insulin for Treatment of Type 2 Diabetes (SURPASS-5)
    Dahl, Dominik
    Onishi, Yukiko
    Norwood, Paul
    Huh, Ruth
    Patel, Hiren
    Rodriguez, Angel
    DIABETES, 2021, 70
  • [34] Efficacy and safety of three dose-escalation algorithms of tirzepatide, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes
    Nauck, M. A.
    Frias, J. P.
    Van, J.
    Benson, C. T.
    Bray, R.
    Milicevic, Z.
    Haupt, A.
    Robins, D. A.
    DIABETOLOGIA, 2019, 62 : S59 - S59
  • [35] Clinical perspectives on the use of the GIP/GLP-1 receptor agonist tirzepatide for the treatment of type-2 diabetes and obesity
    Gallwitz, Baptist
    FRONTIERS IN ENDOCRINOLOGY, 2022, 13
  • [36] Tirzepatide as Monotherapy Improved Markers of Beta-Cell Function and Insulin Sensitivity in People with Type 2 Diabetes (SURPASS-1)
    Lee, Clare
    Mao, Huzhang
    Thieu, Vivian
    Thomas, Melissa K.
    DIABETES, 2022, 71
  • [37] Indices of beta-cell function: association with diabetes control in patients with type 2 diabetes on stable GLP-1 agonist treatment
    Behary, Preeshila
    Godsland, Ian F.
    Baynes, Kevin C.
    PRACTICAL DIABETES, 2014, 31 (05) : 202 - 205
  • [38] GLP-1 Receptor Agonist as Adjuvant Therapy in Type 1 Diabetes: No Apparent Benefit for Beta-Cell Function or Glycemia
    Redondo, Maria J.
    Bacha, Fida
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2020, 105 (08): : E3000 - E3002
  • [39] Effects of tirzepatide (TZP), a novel dual GIP and GLP-1 receptor agonist, on biomarkers of non-alcoholic steatohepatitis (NASH) in patients with type 2 diabetes
    Haupt, A.
    Sanyal, A.
    Loomba, R.
    Wilson, J.
    Bray, R.
    Nikooienejad, A.
    Duffin, K.
    Robins, D.
    Hartman, M.
    DIABETOLOGIA, 2019, 62 : S91 - S91
  • [40] Tirzepatide, a dual GIP/GLP-1 receptor agonist, interrupts metabolic adaptation to dietary restriction
    Coskun, T.
    Roell, W. C.
    O'Farrell, L. S.
    Beebe, E. C.
    Regmi, A.
    Emmerson, P. J.
    Milicevic, Z.
    Haupt, A.
    DIABETOLOGIA, 2020, 63 (SUPPL 1) : S58 - S59
12345